DelveInsight’s Polymyositis pipeline report covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Key Takeaways from the Polymyositis Pipeline Report
Get a detailed analysis of the pipeline landscape @ Polymyositis Pipeline Analysis
Polymyositis Overview
Polymyositis is a type of inflammatory myopathy, a group of muscle diseases marked by chronic muscle inflammation and weakness. Polymyositis (PM) is an autoimmune disorder that develops as a result of abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens and extramural solid muscular expression of major histocompatibility complex 1, which causes damage to the endomysium of skeletal muscles. Polymyositis develops gradually and rarely affects people under the age of 18.
Polymyositis Symptoms
The following are the most common Polymyositis signs and symptoms:
Polymyositis Treatment
Polymyositis is managed using a combination of pharmacological and non-pharmacological treatments. Corticosteroids are the most commonly used pharmacological treatment. Prednisone and methylprednisolone are the most widely used corticosteroids for polymyositis, with a starting dose of 1mg/kg of prednisone per day.
Polymyositis Pipeline Analysis: Drug Profiles
KZR-616: Kezar Life Sciences
Product Description
KZR-616 is a first-in-class selective immunoproteasome inhibitor with broad therapeutic potential in various autoimmune diseases. Through selective immunoproteasome inhibition, KZR-616 provides a novel approach to immune system harmonization.
Phase II
NCT04033926: In January 2020, Kezar Life Sciences launched a Phase II randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and Pharmacodynamics (PD) of KZR-616 treatment in patients with active Polymyositis or Dermatomyositis. During the Screening Period, patients will be evaluated for eligibility.
Polymyositis Pipeline Therapies and Key Companies
Find out the emerging therapies and companies @ Polymyositis Clinical Trials
Polymyositis Therapeutics Assessment
Scope of the Report
Coverage: Global
Polymyositis Key Players: Kezar Life Sciences, Inc, Paean Biotechnology, ImmunoForge, Viela Bio, Cytodyn, among others
Polymyositis Pipeline Therapies: KZR-616, PN-101, PF1801, VIB7734, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Polymyositis: Overview
4.
Pipeline Therapeutics
5.
Late Stage Products (Phase III)
6.
7.
Mid Stage Products (Phase II)
8.
Early Stage Products (Phase I)
9.
10.
Preclinical Stage Products
11.
Therapeutic Assessment
12.
Inactive Products
13.
Collaborations Assessment- Licensing / Partnering / Funding
14.
Polymyositis- Unmet Needs
15.
Polymyositis- Market Drivers and Barriers
16.
Appendix
17.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Key questions answered in the Polymyositis Pipeline Report
Related Reports
Polymyositis Market
DelveInsight’s “Polymyositis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology, and the Polymyositis market trends in the 7MM.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/